SIGNUPABOUTBW_CONTENTSBW_+!DAILY_BRIEFINGSEARCHCONTACT_US


Return to main story


Tissue-Engineering Startups

Dozens of small companies have gone to the public markets in recent years to raise funds for research into tissue repair, replacement, and regeneration. These companies now have a total market capitalization of some $2.5 billion, according to the Rhode Island Center for Cellular Medicine. Most of them, however, will turn a profit only if their experimental treatments make it through several clinical trials and gain approval from the Food & Drug Administration, which can be a risky bet.

Witness what happened to Advanced Tissue Sciences Inc. after the FDA delayed a final decision on its lab-grown skin for diabetic foot ulcers on June 11. The stock, which had already declined from 14 to 7 this year, crashed to a low of 3 1/2 on the news. Still, the creators of those tissues that do succeed will have a good shot at tapping into the $80 billion potential market for engineered tissues.

Though not a comprehensive list, this table includes some of the companies with big plans.




                                                   RECENT

                              52-WEEK              STOCK

COMPANY                  HIGH         LOW          PRICE*



ADVANCED TISSUE          18 1/2       3 1/2        4

SCIENCES (ATIS)



ATRIX LABORA-            23 7/8       11           14 1/2

TORIES (ATRX)



BIOMATRIX                43 1/2       20 5/8       41 7/8

(BIOX)



CREATIVE BIO-            11 5/8       4 1/8        4 9/16

MOLECULES (CBMI)



CYTOTHERAPEUTICS         7 5/8        1 1/16       1 7/16

(CTII)



GUILFORD PHARMA-         32 3/4       16 1/2       17 1/4

CEUTICALS (GLFD)



GENZYME TISSUE           12 1/2       5            6 5/8



INTEGRA                  10 3/4       5 7/8        7 3/8

LIFESCIENCES (IART)



LIFECELL (LIFC)          8 3/8        3 1/2        5 7/8



ORGANOGENESIS            37 51/64     10 41/64     16 1/4

(ORG)



ORTEC INTER-             23           83/8         15 1/2

NATIONAL (ORTC)



REGENERON PHARMA-        13           7            9

CEUTICALS (REGN)





COMPANY                  COMMENTS



ADVANCED TISSUE          New trials on Dermagraft, its living-

SCIENCES (ATIS)          skin product, will have to be done

                         before the FDA will allow commercial

                         distribution. Also working on other

                         uses for its technology, in ortho-

                         pedics and cardiology.

						 

ATRIX LABORA-            Working on systems to grow gum tissue,

TORIES (ATRX)            heal bone fractures, and treat soft

                         tissues.

						 

BIOMATRIX                The success of Synvisc, its treatment

(BIOX)                   for osteoarthritis of the knee, is key

                         to investors now.

						 

CREATIVE BIO-            In trials for a bone-mending product.

MOLECULES (CBMI)         Also developing technology to form

                         cartilage, kidney, tooth, and brain

                         tissues.

						 

CYTOTHERAPEUTICS         Developing therapies for disorders of

(CTII)                   the central nervous system, such as

                         Huntington's and Lou Gehrig's diseases.

						 

GUILFORD PHARMA-         Developing products that will regenerate

CEUTICALS (GLFD)         nerves in Parkinson's disease and in-

                         jured spinal cord victims

						 

GENZYME TISSUE           This separately traded Genzyme division

                         has products for skin repair and replace-

                         ment and is developing bioengineered

                         cartilage.

						 

INTEGRA                  Products induce cells to regenerate body

LIFESCIENCES (IART)      tissues and organs. Gained approval in

                         March 1996 for Integra, a skin-regenera-

                         tion product.

						 

LIFECELL (LIFC)          Working on lab-grown heart valves and

                         dental tissues. Currently markets Allo-

                         Derm, a skin graft used in reconstructive

                         surgery.

						 

ORGANOGENESIS            Makes Apligraf, the first engineered skin

(ORG)                    to win FDA approval for treating leg

                         ulcers. Also working on arteries and an

                         artificial liver.

						 

ORTEC INTER-             This engineered-skin developer is working

NATIONAL (ORTC)          on a skin product for burns and other

                         wounds.

						 

REGENERON PHARMA-        Developing protein-based treatments for

CEUTICALS (REGN)         degenerative neurological diseases, muscle

                         atrophy, and abnormal bone formation.



*As of July 13
DATA: BUSINESS WEEK, BLOOMBERG FINANCIAL MARKETS, TECHVEST LLC, D&MD



RELATED ITEMS

COVER IMAGE: Biotech Bodies

TABLE: The New Era of Regenerative Medicine

GRAPHIC: The New Era of Regenerative Medicine (.pdf)

TABLE: Tissue-Engineering Startups

ONLINE ORIGINAL: INVESTING IN TISSUE ENGINEERING

ONLINE ORIGINAL: A TEENAGER WITH GUTS--AND NOW A CHEST

ONLINE ORIGINAL: THE DYNAMIC DUO OF TISSUE ENGINEERING

ONLINE ORIGINAL: A BLUEPRINT FOR REBUILDING BROKEN SPINAL CORDS



Return to main story


SIGNUPABOUTBW_CONTENTSBW_+!DAILY_BRIEFINGSEARCHCONTACT_US


Updated July 16, 1998 by bwwebmaster
Copyright 1998, Bloomberg L.P.
Terms of Use